The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2
eLife · 19.11.2025 · 14
DOI: 10.7554/elife.103484.3 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 19.11.2025. Verfasst von Rahul K Suryawanshi und 30 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to pose a threat to public health. Current therapeutics remain limited to direct-acting antivirals that lack distinct mechanisms of action and are already showing signs of viral resistance. The virus encodes an ADP-ribosylhydrolase macrodomain (Mac1) that plays an important role in the coronaviral life cycle by suppressing host innate immune responses. Genetic inactivation of Mac1 abrogates viral replication in vivo by potentiating host innate immune responses. However, it is unknown whether this can be achieved by pharmacologic inhibition and can therefore be exploited therapeutically. Here, we report a potent and selective lead small molecule, AVI-4206, that is effective in an in vivo model of SARS-CoV-2 infection. Standard cellular models indicate that AVI-4206 has high target engagement and can weakly inhibit viral replication in a gamma interferon- and Mac1 catalytic activity-dependent manner. However, a stronger antiviral effect for AVI-4206 is observed in human airway organoids and peripheral blood monocyte-derived macrophages. In an animal model of severe SARS-CoV-2 infection, AVI-4206 reduces viral replication, potentiates innate immune responses, and leads to a survival benefit. Our results provide pharmacological proof of concept that Mac1 is a valid therapeutic target via a novel immune-restoring mechanism that could potentially synergize with existing therapies targeting distinct, essential aspects of the coronaviral life cycle. This approach could be more widely used to target other viral macrodomains to develop antiviral therapeutics beyond COVID-19.
Förderung
- National Institutes of Health
Zitieren
APA
Suryawanshi, R. K., Jaishankar, P., Correy, G. J., Rachman, M. M., O'Leary, P. C., Taha, T. Y., Matsui, Y., Zapatero-Belinchón, F. J., McCavitt-Malvido, M., Doruk, Y. U., Stevens, M. G., Diolaiti, M. E., Jogalekar, M. P., Chen, H., Richards, A. L., Kongpracha, P., Bali, S., Montano, M., Rosecrans, J., …, & Fraser, J. S. (2025). The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2. eLife, 14. https://doi.org/10.7554/elife.103484.3
Vancouver
Suryawanshi RK, Jaishankar P, Correy GJ, Rachman MM, O'Leary PC, Taha TY, et al. The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2. eLife. 2025;14. doi:10.7554/elife.103484.3
BibTeX
@article{Suryawanshi2025,
author = {Suryawanshi, Rahul K and Jaishankar, Priyadarshini and Correy, Galen J and Rachman, Moira M and O'Leary, Patrick C and Taha, Taha Y and Matsui, Yusuke and Zapatero-Belinchón, Francisco J and McCavitt-Malvido, Maria and Doruk, Yagmur U and Stevens, Maisie GV and Diolaiti, Morgan E and Jogalekar, Manasi P and Chen, Huadong and Richards, Alicia L and Kongpracha, Pornparn and Bali, Sofia and Montano, Mauricio and Rosecrans, Julia and Matthay, Michael and Togo, Takaya and Gonciarz, Ryan L and Gopalkrishnan, Saumya and Neitz, R Jeffrey and Krogan, Nevan J and Swaney, Danielle L and Shoichet, Brian K and Ott, Melanie and Renslo, Adam R and Ashworth, Alan and Fraser, James S},
title = {The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2},
journal = {eLife},
year = {2025},
volume = {14},
doi = {10.7554/elife.103484.3}
}
EUVIMED